Search results for "Advanced stage"

showing 10 items of 29 documents

Popular uses of wild plant species for medicinal purposes in the Nebrodi Regional Park (North-Eastern Sicily, Italy)

2014

Ethnopharmacological relevance: The area of the Nebrodi Regional Park (North-Eastern Sicily, Italy) has Q3 been quantitatively investigated in an ethnobotanical study for the first time. A total of 90 wild species are used for medicinal purposes and the uses of 5 species have not previously been reported in ethnobotanical studies in Italy (e.g., the use of Arisarum vulgare O. Targ. Tozz. for the treatment of rheumatic pains, the use of Silene vulgaris (Moench) Garcke for the treatment of liver diseases). Aim of the study: The aim of this paper was to understand to what extent current knowledge on the medicinal use of plants is still an element of the culture within the rural populations of …

MaleRural PopulationWild speciesClinopodium nepetaMalva sylvestrisBrassica rupestris Raf.foodDrug DiscoveryBrassica rupestrisHumansMediterranean folk medicineNebrodi Regional ParkSicilyAgedSilene vulgarisAged 80 and overPharmacologyPlants MedicinalbiologyTraditional medicineAgroforestryData CollectionSettore BIO/02 - Botanica SistematicaAdvanced stageCultural erosionbiology.organism_classificationEthnobotanical indicefood.foodSettore AGR/02 - Agronomia E Coltivazioni ErbaceeGeographyEthnobotanySettore BIO/03 - Botanica Ambientale E ApplicataPlant speciesFemaleMedicine TraditionalPlant PreparationsPhytotherapy
researchProduct

Interleukin‐6 concentration changes in plasma and saliva in bisphosphonate‐related osteonecrosis of the jaws

2013

To determine the plasma and saliva levels of IL-6 in patients with bisphosphonate-related osteonecrosis of the jaws (BRONJ) and to investigate whether there is a correlation between more advanced stages of BRONJ and levels of IL-6.We studied three groups: group 1 consisted of 30 patients with BRONJ due to intravenous bisphosphonates (ivBP), group 2 consisted of 25 patients treated with ivBP but without BRONJ, and group 3 consisted of 15 healthy controls. In each case, we assayed plasma and saliva IL-6 samples using an ELISA test.Significantly, higher IL-6 values were found in both saliva and plasma in group 1 vs groups 2 and 3 (P  0.01). Group 1 showed no differences in plasma or saliva IL-…

Malemedicine.medical_specialtySalivamedicine.medical_treatmentDentistryGastroenterologyInternal medicinemedicineHumansIn patientStage (cooking)SalivaInterleukin 6General DentistryAgedDiphosphonatesbiologyInterleukin-6business.industryAdvanced stageBisphosphonateOtorhinolaryngologyElisa testbiology.proteinEtiologyBisphosphonate-Associated Osteonecrosis of the JawFemalebusinessOral Diseases
researchProduct

Different Surgical Approaches to Treat Chronic Tophaceous Gout in the Hand: Our Experience

2010

Chronic tophaceous gout is a disabling erosive arthritis characterized by an elevated serum urate concentration, recurrent attacks of arthritis, and deposits of monosodium urate crystals in synovial fluids. Tophi, ulcerations of the overlying skin, and fissures of the interarticular cartilage may occur in advanced stages, combined with deformities of the joints and decreased active joint flexion and extension. Although the timely use of allopurinol is associated with a decrease in the frequency of deposits of the tophaceous substance, however, surgical management is necessary to restore and improve the cosmesis and joint function, to alleviate symptomatic discomfort, and to reduce the risk …

Malemusculoskeletal diseasesmedicine.medical_specialtyAllopurinolArthritismedicineHumansOrthopedics and Sports MedicineSurgical approachArthritis Goutybusiness.industryCartilageAdvanced stageCosmesisPlastic Surgery ProceduresHandmedicine.diseaseSurgerymedicine.anatomical_structureChronic tophaceous goutChronic DiseaseJoint flexionFemaleSurgerybusinessmedicine.drugTechniques in Hand & Upper Extremity Surgery
researchProduct

Hepatic vein tumor thrombosis in patients with hepatocellular carcinoma: Prevalence and clinical significance.

2021

Abstract Background There is strong evidence that portal vein tumor thrombosis (PVTT) is associated with poor survival in patients with hepatocellular carcinoma (HCC). However, data regarding the clinical significance of hepatic vein tumor thrombosis (HVTT) is rare, particularly in Western patients. Objective To determine the HVTT prevalence in a Western patient population and its impact on survival. Methods We included 1310 patients with HCC treated in our tertiary referral center between January 2005 and December 2016. HVTT and PVTT were diagnosed with contrast‐enhanced cross‐sectional imaging. Overall survival (OS) was calculated starting from the initial HCC diagnosis, and in a second s…

Maletumor thrombosismedicine.medical_specialtytumorCarcinoma HepatocellularKaplan-Meier EstimateHepatic VeinsGastroenterologysurvival03 medical and health sciences0302 clinical medicineInternal medicineGermanymedicinePrevalenceHumansIn patientClinical significanceNeoplasm InvasivenessRisk factorVeinAgedRetrospective StudiesVenous Thrombosishepatic vein thrombosisbusiness.industryPortal VeinAdvanced stageLiver NeoplasmsGastroenterologyhepatocellular carcinomaMiddle Agedmedicine.diseaseThrombosismedicine.anatomical_structureOncology030220 oncology & carcinogenesisHepatocellular carcinomaMultivariate AnalysisReferral center030211 gastroenterology & hepatologyFemaleOriginal ArticleHepatobiliarybusinessUnited European gastroenterology journal
researchProduct

Expression of selected molecular factors in two types of endometrial cancer

2021

BACKGROUND Endometrial cancers (EC) are a heterogeneous group of malignant neoplasms differing in etiology, clinical-pathological features and prognosis. OBJECTIVES To determine the differences between the expression of selected molecular factors and find connections between them in order to isolate possible biomarkers influencing treatment options. MATERIAL AND METHODS The investigated data involved archival histological preparations obtained from uterine EC samples taken from 137 patients, treated surgically between 2007 and 2014. The immunohistochemical Dako EnVisionTM Flex+ method was applied. RESULTS The expression of ERβ, MLH1 and BRCA1 was lower in ECI than in ECII patients. The ERα …

Medicine (miscellaneous)BiologyMLH1General Biochemistry Genetics and Molecular BiologyMYH9AndrologyInternal MedicinemedicineHumansPharmacology (medical)Stage (cooking)Grading (tumors)Genetics (clinical)Neoplasm StagingHeterogeneous groupFAKEndometrial cancerAdvanced stageTreatment optionsBAPPrognosismedicine.diseaseEndometrial Neoplasmsendometrial cancerReviews and References (medical)ImmunohistochemistryFemaleAdvances in Clinical and Experimental Medicine
researchProduct

Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions

2013

The intermediate stage of hepatocellular carcinoma (HCC) comprises a highly heterogeneous patient population and therefore poses unique challenges for therapeutic management, different from the early and advanced stages. Patients classified as having intermediate HCC by the Barcelona Clinic Liver Cancer (BCLC) staging system present with varying tumor burden and liver function. Transarterial chemoembolization (TACE) is currently recommended as the standard of care in this setting, but there is considerable variation in the clinical benefit patients derive from this treatment.In April 2012, a panel of experts convened to discuss unresolved issues surrounding the application of current guidel…

NiacinamideOncologymedicine.medical_specialtyCarcinoma HepatocellularStandard of careTumor burdenAntineoplastic AgentsGastroenterologyAntineoplastic AgentInternal medicinemedicineHumansChemoembolization TherapeuticStaging systemHepatologybusiness.industryPhenylurea CompoundsLiver NeoplasmsAdvanced stageSorafenibmedicine.diseasedigestive system diseasesLiver NeoplasmHepatocellular carcinomaLiver functionTreatment decision makingLiver cancerbusinessHumanSeminars in Liver Disease
researchProduct

Qol and adherence to i.v. or oral chemotherapy treatment in elderly patients with advanced NSCLC.

2012

e18002 Background: In elderly patients with advanced stage NSCLC the identification of the best treatment-related quality of life becomes the main discriminating endpoint. Methods: In this multicentre study, 53 elderly (≥ 70 yrs) patients with advanced (IIIB-IV) NSCLC were randomly allocated to receive as first-line treatment either Gemcitabine intravenously (1000 mg/m2) or oral Vinorelbine (60 mg/m2) both on days 1 and 8, every 21 days. The primary objective was the evaluation of the QoL, while the secondary one was the assessment of treatment adherence. The EORTC QLQ-C30 v 2.0 and QLQ-LC13 questionnaires have been used to evaluate the quality of life and an “ad hoc” questionnaire for the…

OncologyCancer Researchmedicine.medical_specialtyOncologyQuality of lifeOral chemotherapybusiness.industryInternal medicineAdvanced stagemedicinebusinesshumanitiesSurgeryJournal of Clinical Oncology
researchProduct

Tumor mutational burden on cytological samples: A pilot study.

2020

Background Immune-checkpoint inhibitors (ICIs) represent an important treatment option for patients who have advanced stage non-small cell lung cancer (NSCLC). Currently, evaluation of the expression level of programmed death-ligand 1 (PD-L1) has proven highly successful as a positive predictive biomarker for ICIs. In addition to PD-L1, other promising predictive biomarkers are emerging, including high tumor mutational burden (TMB-H). However, measuring TMB-H remains challenging for several reasons, among which is the difficulty in obtaining adequate tissue material from NSCLC patients. There are no data in the current literature regarding the possibility of adopting cell blocks (CBs) for T…

OncologyMaleCancer Researchmedicine.medical_specialtyLung NeoplasmsCytological TechniquesDNA Mutational Analysis030209 endocrinology & metabolismPilot Projects03 medical and health sciences0302 clinical medicineInternal medicineCarcinoma Non-Small-Cell LungmedicineBiomarkers TumorHumansLung cancerPredictive biomarkerAgedRetrospective Studiesnext generation sequencingTMBbusiness.industryAdvanced stageTreatment optionsHigh-Throughput Nucleotide SequencingIon semiconductor sequencingAmpliconmedicine.diseasePrognosislung cancerOncology030220 oncology & carcinogenesisMutationcytologyTissue materialFemaleimmunotherapyNon small cellbusinessFollow-Up StudiesCancer cytopathologyReferences
researchProduct

53P Role of immune biomarkers in evaluating predictive and prognostic value in advanced stage HER2 positive breast cancer

2020

Oncologymedicine.medical_specialtyImmune systemOncologybusiness.industryInternal medicineHER2 Positive Breast CancerAdvanced stageMedicineHematologybusinessValue (mathematics)Annals of Oncology
researchProduct

Liquid Biopsy in Gynecological Cancers

2017

Gynecological cancers originate in woman’s reproductive organs, including ovarian, uterine or endometrial, cervical, vulvar, and vaginal cancers. These tumors are a leading health problem for women accounting for more than 20% of new cases and cancer-related deaths worldwide. Gynecological cancers are characterized by an aggressive biological behavior with a clinical presentation often in advanced stage of disease. This chapter will focus on the potential role of the novel molecular approaches based on liquid biopsy in detecting occult disease, monitoring the progression and identifying treatment-resistance in gynecological cancer patients. The ability to detect circulating tumor DNA (ct-DN…

Oncologymedicine.medical_specialtyPathologySettore MED/06 - Oncologia Medicabusiness.industryAdvanced stageOccult diseaseDiseaseGynecological cancerMolecular biomarkersExosomect-DNA Gynecological cancers high throughput sequencing technologiesInternal medicinemedicinePersonalized medicineLiquid biopsybusiness
researchProduct